Item 7.01. Regulation FD Disclosure.
On August 1, 2022, Aerie Pharmaceuticals, Inc. (the “Company”) issued a press
release announcing that the first patient has been dosed in the Phase 3
registrational study, named COMET-3, to evaluate AR-15512 ophthalmic solution as
a treatment for the signs and symptoms of dry eye disease. A copy of this press
release is furnished as Exhibit 99.1 hereto and is hereby incorporated by
reference into this Item 7.01.
The information in this Item 7.01 (including Exhibit 99.1) is being furnished,
not filed, pursuant to Regulation FD. Accordingly, the information in this Item
7.01 will not be incorporated by reference into any registration statement filed
by the Company under the Securities Act of 1933, as amended, unless specifically
identified therein as being incorporated therein by reference. The furnishing of
the information in this Item 7.01 is not intended to, and does not, constitute a
determination or admission by the Company that this information is material or
complete, or that investors should consider this information before making an
investment decision with respect to any security of the Company.
Item 9.01. Financial Statements and Exhibits.
The following exhibit relating to Item 7.01 shall be deemed to be furnished, and
99.1 Press Release Dated August 1, 2022. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
© Edgar Online, source Glimpses